Close Menu

MDxHealth

NEW YORK (GenomeWeb News) – MDxHealth today said that revenues in the fourth quarter increased 89 percent year over year, though its net loss widened.

Dako, Pfizer Ink Arrangement to Advance Companion Diagnostics
Agilent subsidiary Dako has inked an agreement with Pfizer to collaborate on multiple projects in the field of companion diagnostics.

A new partnership between diagnostics manufacturer MDxHealth and Ghent University's laboratory of pharmaceutical biotechnology aims to develop epigenomics-based diagnostics for more personalized treatment of cancers and inflammatory diseases.

NEW YORK (GenomeWeb News) – MDxHealth and Ghent University announced today that they have formed a new epigenetics research center to accelerate innovations in personalized medicine.

NEW YORK (GenomeWeb News) – MDxHealth said today that revenues in the third quarter rose 145 percent year over year, driven by a 141 percent increase in commercial revenues.

Drug developer Clovis Oncology is planning to report data from a clinical trial later this year that may yield a new treatment option for pancreatic cancer patients who are poor responders to gemcitabine.

NEW YORK (GenomeWeb News) – MDxHealth today reported that its first-half 2012 revenues climbed 43 percent on a sharp uptick in commercial revenues.

NEW YORK (GenomeWeb News) – Sorenson Genomics and MDxHealth today separately announced they have each received accreditation from the College of American Pathologists.

Merck KGaA and MDxHealth have extended an existing personalized medicine research collaboration so that the drug firm will fund the development, regulatory activities, and commercial launch of a companion diagnostic being advanced by MDxHealth for an investigational glioblastoma

NEW YORK (GenomeWeb News) – MDxHealth today announced its collaborative agreement with Merck KGaA has been expanded to include the continued development and worldwide commercialization of MDxHealth's PredictMDx for Glioblastoma test.

Pages

A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.

Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.

The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.

In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.